Guardant Health to Present Precision Oncology Data Across the Continuum of Care at the ASCO Annual Meeting
Guardant Health, Inc. (GH)
Last guardant health, inc. earnings: 2/24 04:03 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
REDWOOD CITY, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), along with researchers from leading academic institutions and pharmaceutical companies, will present 27 abstracts at the ASCO Annual Meeting detailing new insights into precision oncology generated from its commercially available Guardant360 and GuardantOMNI assays, as well as its research-use-only (RUO) LUNAR liquid biopsy. For patients with advanced cancer, these include multiple investigations of the GuardantOMNI assay’s ability to identify patients who may benefit from treatment with immunotherapy. Additionally, researchers will present Guardant360 data to demonstrate the effectiveness of new targeted drugs, as well as the feasibility of serial ctDNA analysis to rapidly predict treatment response and long-term clinical benefit. For patients with early stage disease, the presentations include an analytical validation of Guardant’s LUNAR assay (Abstract 3057), as well as a pilot study expl
Show less
Read more
Impact Snapshot
Event Time:
GH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GH alerts
High impacting Guardant Health, Inc. news events
Weekly update
A roundup of the hottest topics
GH
News
- Guardant Health, Inc. (NASDAQ: GH) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $32.00 to $28.00. They now have a "buy" rating on the stock.MarketBeat
- Guardant Health, Inc. (NASDAQ: GH) had its "neutral" rating re-affirmed by analysts at Guggenheim.MarketBeat
- Plug and Play Welcomes First Silicon Valley Startup Batches of 2024 [Yahoo! Finance]Yahoo! Finance
- Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual MeetingBusiness Wire
GH
Earnings
- 2/22/24 - Beat
GH
Sec Filings
- 4/12/24 - Form SC
- 4/5/24 - Form 4
- 4/2/24 - Form 4
- GH's page on the SEC website